SG Americas Securities
CLVS

SG Americas Securities’s Clovis Oncology, Inc. CLVS Stock Holding History

SG Americas Securities’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-300,000
Closed -$1.77M – 3546
2018
Q2 		$1.77M Buy
+300,000
New +$14.6M 0.02% 1005
2018
Q1 		– Sell
-150,000
Closed -$1.38M – 3637
2017
Q4 		$1.38M Buy
+150,000
New +$10.5M 0.01% 1135

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

SG Americas Securities's CLVS Position: Q2 2022 in Review

SG Americas Securities sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 23,756 shares — an estimated $48K sold.

SG Americas Securities first reported a position in CLVS in Q3 2013 and held it in 28 quarters. The position peaked at $3.81M in Q1 2020. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

  • SG Americas Securities reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
  • SG Americas Securities sold 23,756 Clovis Oncology, Inc. shares in Q2 2022, an estimated $48K.
  • SG Americas Securities first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 28 quarters.
  • SG Americas Securities's Clovis Oncology, Inc. position peaked at $3.81M in Q1 2020.
  • 115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on SG Americas Securities's 13F filing for Q2 2022, filed 29 Jul 2022.